OKAVA Announces Publication of Groundbreaking Pilot Study on Atopic Dermatitis in Dogs
Study Offers New Hope for Canine Patients Poorly Controlled with Conventional Treatments
OKAVA Announces the Appointment of New Board Members and Strategic Advisors
Enhanced Board of Directors will play a crucial role in advancing OKAVA’s mission to redefine pet care
OKAVA’s Announces Publication of OKV-119, A Drug Delivery System Under Development for Feline Obesity and Diabetes
Study Published in BMC Veterinary Research Highlights Months-Long Exenatide Drug Delivery Achieved Through OKAVA’s Innovative OKV-119 Drug Delivery System
OKAVA’s Breakthrough Pilot Study on Canine Atopic Dermatitis Chosen for Oral Presentation at the World Congress of Veterinary Dermatology
Study Offers New Hope for Canine Patients Poorly Controlled with Conventional Treatments
OKAVA Announces Publication of a Proof-of-Concept Validation Study for OKV-119, Its Pioneering Long-Term Drug Delivery System
Published in Frontiers in Veterinary Research, the Feasibility of Long-Term Drug Delivery of the GLP-1 Exenatide is Demonstrated in this Study Conducted in Cats
OKAVA Announces Publication of Proof-of-Concept Validation Studyfor OKV-1001, Its Pioneering Modified Release Mycophenolate Product for Immune-Mediated Diseases
Published in Frontiers in Veterinary Research, This Proof-of-Concept Study Demonstrates the Clinical Advantages of OKV-1001 Over Immediate-Release CellCept®
OKAVA Awarded $500,000 Grant by the FDA for Clinical Trial of OKV-1001 for the Treatment Blood Disorder
The Competitive Grant Awarded to OKAVA Demonstrates That the FDA Considers
OKV-1001 To Be an Innovative Product That Addresses High Unmet Medical Need
OKAVA Announces Receipt of MUMS Drug Designation in Dogs for OKV-1001
MUMS Designation Places OKV-1001 on an Accelerated Conditional Approval
Pathway and Demonstrates That the FDA Considers OKV-1001 To Be an Innovative
Product That Addresses High Unmet Medical Need
OKVA Announces Collaboration with Nano Precision Medical, Inc. on Long-Term Drug Delivery System to Develop Novel Therapeutics for Animal Health
Collaboration Leverages NanoPortal™, A Best-in-Class Drug-Device Technology Developed by Nano Precision Medical, For Use in Feline Obesity and Diabetes
OKAVA Announces Positive FDA Pre-Submission Conference For OKV-1001 To Treat A Deadly Blood Disorder In Dogs
A Clear Path to Regulatory Approval Has Been Established For the Use Of OKV-
1001 in IMHA
